Who Else Wants A Joint Of Staurosporine ?

002 and P http://www.selleckchem.com/products/epz-5676.html features of the treated group to 60 consecutive patients who did not receive any form of neoadjuvant therapy before PD (untreated group) during the same time period at our institution. The median OS in the treated group was 33.5 months (��2.5 months) and was better than the median OS of 26.5 months (��3.4 months) in the untreated group (P = .04, Fig. 3A). The median DFS was also better in the treated group than the untreated group; however, the difference in DFS between these 2 groups was not statistically significant (P = .08, Fig. 3B). In the http://www.selleckchem.com/products/ly2109761.html treated group, metastatic PDAC was identified in 58% (140 of 240) of the patients, which was significantly lower than the untreated group (75% [45 of 60], P = .01). There were no significant differences in tumor size, differentiation, margin status, and other clinical parameters between these 2 groups (data not shown). In this study, we found that post-therapy http://www.selleck.cn/products/Staurosporine.html pathologic AJCC stage and the number of positive regional lymph nodes are independent prognostic factors for both DFS and OS in a consecutive cohort of 240 patients with PDAC who received neoadjuvant chemoradiation followed by PD treated at a single institution. In addition, our study also found that tumor differentiation, ypT, and margin status are independent prognostic factors for OS. Our study highlights the importance of pathologic evaluation and post-therapy tumor staging in predicting prognosis of patients with PDAC who received neoadjuvant therapy and subsequently underwent PD. In the treatment of patients with PDAC, neoadjuvant therapy has several potential advantages, including identifying patients who are likely to benefit the most from surgery, providing early treatment of micrometastatic disease, and potentially down-staging the tumor in borderline resectable cases, thereby increasing the rate of complete resection and reducing local recurrence.